Safety profile of autologous macrophage therapy for liver cirrhosis-Reference-Cited by-同舟云学术

Safety profile of autologous macrophage therapy for liver cirrhosis

Published:2019-10 Issue:10 Volume:25 Page:1560-1565
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Moroni Francesca,Dwyer Benjamin J.,Graham Catriona,Pass Chloe,Bailey Laura,Ritchie Lisa,Mitchell Donna,Glover Alison,Laurie Audrey,Doig Stuart,Hargreaves Emily,Fraser Alasdair R.^ORCID,Turner Marc L.,Campbell John D. M.,McGowan Neil W. A.,Barry Jacqueline,Moore Joanna K.,Hayes Peter C.,Leeming Diana J.,Nielsen Mette J.,Musa Kishwar,Fallowfield Jonathan A.^ORCID,Forbes Stuart J.^ORCID

Funder

RCUK | Medical Research Council

RCUK | MRC | Medical Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-019-0599-8.pdf

Reference34 articles.

1. Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).

2. D’Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217–231 (2006).